Peninsula drugmaker divests biosimilar eye drug for $170M cash

The drug, a lookalike version of Genentech’s Lucentis for wet age-related macular degeneration and other eye conditions, was licensed in 2019 by Coherus.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks